Development of a simplified, sensitive high-performance liquid chromatographic method using fluorescence detection to determine the concentration of UCN-01 (cas 112953-11-4) in human plasma
-
Add time:07/31/2019 Source:sciencedirect.com
UCN-01 (cas 112953-11-4) is a naturally derived anticancer agent isolated in the culture broth of actinomyces streptomyces. We have developed a sensitive high-performance liquid chromatographic method for the determination of UCN-01 in human plasma. UCN-01 was isolated from human plasma after intravenous administration, by using 100% ice-cold acetonitrile liquid–liquid phase extraction. Liquid chromatographic separation was achieved by isocratic elution on a phenyl analytical column. The mobile phase consisted of acetonitrile–0.5 M ammonium acetate (45:55) with 0.2% triethylamine added as a modifier. The UCN-01 peak was identified from other peaks using fluorescence excitation energy and emission energy wavelengths of 310 and 410 nm, respectively. Retention time for UCN-01 was 4.2±0.5 min. The UCN-01 peak was baseline resolved, with nearest peak at 2.6 min distance. No interfering peaks were observed at the retention time of UCN-01. Peak area amounts from extracted samples were proportional over the dynamic concentration range used: 0.2 to 30 μg/ml. Mean recoveries of UCN-01 at concentrations of 0.5 and 25 μg/ml were 89 and 90.2%, respectively. Relative standard deviations for UCN-01 calibration standards ranged from 1.89 to 2.31%, with relative errors ranging from 0.3 to 11.6%. Assay precision for UCN-01 based on quality control samples of 0.50 μg/ml was ±4.86% with an accuracy of ±5.7%. For drug extracted from plasma the lowest limit of detection was 0.1 μg/ml, with the lowest limit of quantitation being 0.2 μg/ml. This method is suitable for routine analysis of UCN-01 in human plasma at concentration from 0.2 to 30 μg/ml.
We also recommend Trading Suppliers and Manufacturers of UCN-01 (cas 112953-11-4). Pls Click Website Link as below: cas 112953-11-4 suppliers
Prev:MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 (cas 112953-11-4) by exacerbating radiation-induced aberrant mitosis
Next:AG490 influences UCN-01 (cas 112953-11-4)-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- UCN-01 (cas 112953-11-4), an anti-tumor drug, is a selective inhibitor of the conventional PKC subfamily08/05/2019
- Controlled release of a protein kinase inhibitor UCN-01 (cas 112953-11-4) from liposomes influenced by the particle size08/04/2019
- UCN-01 (cas 112953-11-4) in combination with topotecan in patients with advanced recurrent ovarian cancer: A study of the Princess Margaret Hospital Phase II consortium08/03/2019
- Development of a highly sensitive high-performance liquid chromatographic method for measuring an anticancer drug, UCN-01 (cas 112953-11-4), in human plasma or urine08/02/2019
- AG490 influences UCN-01 (cas 112953-11-4)-induced cytotoxicity in Glioma cells in a p53-dependent fashion, correlating with effects on BAX cleavage and BAD phosphorylation08/01/2019
- MK-8776, a novel Chk1 inhibitor, exhibits an improved radiosensitizing effect compared to UCN-01 (cas 112953-11-4) by exacerbating radiation-induced aberrant mitosis07/30/2019
- The phosphoinositide-dependent protein kinase 1 inhibitor, UCN-01 (cas 112953-11-4), induces fragmentation: Possible role of metalloproteinases07/29/2019
- Celecoxib Enhances the Radiosensitizing Effect of 7-Hydroxystaurosporine (UCN-01 (cas 112953-11-4)) in Human Lung Cancer Cell Lines07/28/2019
- The combination of UCN-01 (cas 112953-11-4) and ATRA triggers differentiation in ATRA resistant acute promyelocytic leukemia cell lines via RAF-1 independent activation of MEK/ERK07/27/2019